Novel role of plasmacytoid dendritic cells in humans: Induction of interleukin‐10–producing treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy
- 28 December 2009
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 62 (1), 53-63
- https://doi.org/10.1002/art.25037
Abstract
Objective Reestablishing immune tolerance and long‐term suppression of disease represent major therapeutic goals in rheumatoid arthritis (RA). Dendritic cells (DCs) likely play a central role in such regulation via the expansion and/or induction of Treg cells. The present study was undertaken to explore the contribution of DCs to the development of Treg cells in a human autoimmune disease setting. Methods DC subsets were characterized by flow cytometry in the peripheral blood and synovial fluid of patients with RA. Proliferation of and cytokine release by naive CD4+CD25− T cells were measured in cocultures of these cells with DCs from patients with RA and healthy controls. The suppressive capacity of DC‐polarized T cells was explored in vitro by a standard suppression assay. Results Only very low numbers of both plasmacytoid DCs (CD303+) and myeloid DCs (CD1c+) were present in the peripheral blood of patients with active RA. In contrast, patients with therapy‐induced remission of RA exhibited higher numbers of circulating plasmacytoid DCs. Mature plasmacytoid DCs from RA patients with low disease activity, but not those from healthy controls, expressed high levels of indoleamine 2,3‐dioxygenase and promoted the differentiation of allogeneic naive CD4+CD25− T cells into interleukin‐10–secreting Treg cells, or Tr1 cells, that showed poor proliferation in vitro. Importantly, these plasmacytoid DC–primed Treg cells potently suppressed the proliferation of autologous naive CD4+ T cells, in a dose‐dependent manner. Conclusion These results demonstrate, for the first time, that human plasmacytoid DCs may be educated within the rheumatoid microenvironment to acquire a tolerogenic phenotype. Modulation of the immune response by plasmacytoid DCs might provide novel immune‐based therapies in autoimmunity and transplantation.Keywords
This publication has 47 references indexed in Scilit:
- Rheumatoid arthritisLancet, 2009
- Therapeutic effect of exosomes from indoleamine 2,3‐dioxygenase–positive dendritic cells in collagen‐induced arthritis and delayed‐type hypersensitivity disease modelsArthritis & Rheumatism, 2009
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3 + CD4 + regulatory T cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseJCI Insight, 2007
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- CD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFN-γ, and indoleamine 2,3-dioxygenaseJCI Insight, 2007
- Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligandThe Journal of Experimental Medicine, 2007
- Anti–TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-βThe Journal of Experimental Medicine, 2007
- Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα TherapyThe Journal of Experimental Medicine, 2004
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988